Hints and tips:
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Drugmakers GSK and Boehringer Ingelheim are now rationing inhalers, according to Premier....
...Ingelheim, after it received approval....
...Another company, Boehringer Ingelheim of Germany, remains in patent litigation with AbbVie and has no plans for a European launch, despite its medicine being approved for sale in the EU....
...That would have been close to the multiple of 22 times operating earnings before usual deductions used to price Sanofi’s €21.8bn asset swap with Boehringer Ingelheim last year....
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...Addyi was first developed as an antidepressant in the 1990s by Boehringer Ingelheim, the German pharmaceuticals group, but failed to make it through clinical trials....
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...Ingelheim in July....
...Andreas Barner, chairman of Boehringer Ingelheim said: Boehringer Ingelheim Animal Health is and will stay strongly committed to bringing novel, innovation driven solutions to veterinarians and animal owners...
...Jordan-founded but UK-listed Hikma initially agreed to buy the business from Boehringer Ingelheim in July, declaring that the deal would transform its scale and position in the US....
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...Sanofi last month completed a €22.8bn asset swap with Boehringer Ingelheim, which allowed the French group to trade its animal health unit and gain a new consumer-health focused business as well as a €4.7bn...
...GlaxoSmithKline and Novartis swapped oncology and vaccine assets in 2015; on Tuesday, Sanofi and Boehringer Ingelheim said they were in talks about swapping their animal and consumer health divisions....
...The first was an €18bn asset swap with Boehringer Ingelheim agreed last December, which, once completed, will see Sanofi trade its animal health unit for the German group’s consumer health business....
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...In December 2015, Sanofi entered talks with Boehringer Ingelheim over an €18bn asset exchange that would see the French drugmaker swap its animal health unit for the German company’s consumer health business...
...Possible buyers include Zoetis and pharma groups that still have animal health divisions: Lilly, Bayer and possibly Boehringer Ingelheim, which is privately held....
...Based on 2014 revenues, the combined entity would have ranked 21st among global pharma groups with $12bn of sales, behind Boehringer Ingelheim but above big names such as Biogen....
...First in line will be flibanserin, a drug originally submitted to the FDA by Boehringer Ingelheim of Germany and rejected in 2010, on the grounds that its benefits did not outweigh side-effects....
...Boehringer Ingelheim of Germany filed for information on InterMune’s products. Both rivals were developing similar compounds....
...Christian Boehringer, chairman of Boehringer Ingelheim, warned of a threat to Europe’s healthcare systems as governments sought to save costs....
International Edition